Back
Acrivon Therapeutics
Technologies for the treatment of cancer
Company website ↗About
Acrivon Therapeutics, Inc. specializes in developing drugs to treat cancer. The company has one candidate drug, ACR-368, in phase one of clinical trials as a combination therapy and in phase two as a monotherapy for several types of cancer.
ACR-368 is a selective low-molecular-weight inhibitor currently being tested to treat difficult-to-treat cases of endometrial, bladder, and ovarian cancer that are resistant to other therapies.
The company's main development is the Acrivon Predictive Precision Proteomics (AP3) research platform, designed to identify targeted drugs against cancer. Such drugs have already been created by other companies, but they are usually highly specialized and effective for only about 10% of cases with clearly defined mutations. The AP3 platform allows for the quick selection of the most effective targeted therapy for specific patients.
Acrivon's related development is the ACR-368 OncoSignature test for cancer diagnosis. It has not yet been approved, but it has successfully passed trials conducted by the American National Cancer Institute and Eli Lilly.
________________________
Number of employees:
25-50
________________________
Headquarters location:
Watertown, Massachusetts, USA
Underwriters
Surveyor Capital, Wellington Management
Calls within Tajikistan are free
Investments
Information
The information provided is for informational purposes only and should not be considered as an offer to buy or sell foreign currency, securities and/or other financial instruments. The information presented on this website is not an individual investment recommendation. Financial instruments or transactions mentioned in this section may not be suitable for you, may not correspond to your investment profile, financial situation, investment experience, knowledge, investment objectives, attitude to risk and profitability.
LLC "Exchange Broker" does not guarantee and does not promise future profitability of investments, does not guarantee the reliability of possible investments and the stability of possible income. Investment results in the past do not guarantee income in the future.
LLC "Exchange Broker" is not responsible for possible investor losses in the event of transactions and investments in financial instruments, and also does not guarantee the return, effectiveness and profitability of investments.
LLC "Exchange Broker" hereby informs that it operates in the securities market in accordance with the following professional participant licenses issued by the Ministry of Finance of the Republic of Tajikistan: depository activity No.010/25 dated 25.06.2025; brokerage activity No.007/25 dated 25.06.2025; dealer activity No.008/25 dated 25.06.2025 and securities management activity No.009/25 dated 25.06.2025, and also informs about the risk of a conflict of interest, including as a result of combining various types of professional activity in the securities market.